Home › Companies › IMNM

Pipeline (9 active programs)

Technology platforms

Capital (as filed)

Cash

$218M cash and cash equivalents · Jun 30, 2026 (10-Q)

Short-term investments

$302M Jun 30, 2026

Operating cash flow

−$61.7M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$425M cash per the update of Oct 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

• 2026-11-05 UPDATE: Immunome (IMNM) - The Canary Sings 🔒 Paid
• 2026-10-06 UPDATE: Immunome (IMNM) - Buying Out the Landlord 🔒 Paid
• 2026-08-12 UPDATE: Immunome (IMNM) - The Clock Is Set, and It Runs Long 🔒 Paid
• 2026-06-22 Immunome, Inc. (IMNM) — Scientific Deep Dive for Varegacestat and the HC74 ADC Pipeline 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Immunome, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-06-22 Watch Immunome, Inc. (IMNM) — Scientific Deep Dive for Varegacestat and the HC74 ADC Pipeline Positive Phase 3 and NDA filed, but rich ~$1.8B EV after a +200% run, low-teen BMS royalty drag, 80% dose-reduction safety tab, EcoR1 trimming, and second-mover launch against Merck KGaA-backed incumbent warrant waiting for a better entry or launch traction evidence.
2. 2026-08-12 Watch UPDATE: Immunome (IMNM) - The Clock Is Set, and It Runs Long FDA accepted the NDA with an April 2027 PDUFA (standard review), valuation expanded ~39% on procedural news, burn running above model, and the second-mover discount deserves to widen with delay — still waiting for a better entry or IM-1021 data.
3. 2026-10-06 Watch UPDATE: Immunome (IMNM) - Buying Out the Landlord BMS royalty and milestone obligations eliminated for ~$113M (cash + stock), improving per-share economics and M&A appeal, but a confirmed upgrade still needs the IM-1021 lymphoma readout; accumulating on weakness worth considering, especially on BMS resale dips.
4. 2026-11-05 Speculative buy speculative UPDATE: Immunome (IMNM) - The Canary Sings IM-1021 delivered first human evidence of HC74 platform efficacy (53% ORR in B-NHL, 64% in DLBCL after T-cell therapies), BMS royalty already eliminated, stock below pre-run-up levels — the gating event arrived and the entry is better, but n=19 with no durability data and 44% grade ≥3 neutropenia keep it speculative pending December ASH update.

• Long call · opened Nov 5, 2026 at $17.91 · +4.5% vs XBI +2.6% (Nov 6, 2026)

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (9 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

• 2026-08-11 10-Q in filings ↓

  • “IND-enabling work for IM-1335 is ongoing and we expect to submit an IND for this program to the FDA in late 2026.”

    matched to IM-1335 · regulatory submission · read as late 2026

  • “IND-enabling work for IM-1340 is ongoing and we expect to submit an IND for this program to the FDA in mid-2026.”

    matched to IM-1340 · regulatory submission · read as mid-2026

  • “We submitted a new drug application, or NDA, for varegacestat in April 2026, which has been accepted by the U.S. Food and Drug Administration, or FDA, and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027.”

    matched to Varegacestat · regulatory decision · read as April 28, 2027
• 2026-08-11 8-K in filings ↓

  • “Preclinical ADC Pipeline : Immunome expects to submit Investigational New Drug applications (INDs) for IM-1340 and IM-1335 in mid- and late 2026, respectively.”

    matched to IM-1335 · regulatory submission · read as late 2026

  • ““For varegacestat, the presentation of detailed Phase 3 RINGSIDE data at ASCO and subsequent FDA acceptance of our NDA with a PDUFA target action date of April 28, 2027 represent important steps toward a potential approval and launch.”

    matched to Varegacestat · regulatory decision · read as April 28, 2027
• 2026-08-11 10-Q in filings ↓

  • “IND-enabling work for IM-1335 is ongoing and we expect to submit an IND for this program to the FDA in late 2026.”

    matched to IM-1335 · regulatory submission · read as late 2026

  • “Preclinical ADC Pipeline : Immunome expects to submit Investigational New Drug applications (INDs) for IM-1340 and IM-1335 in mid- and late 2026, respectively.”

    matched to IM-1335 · regulatory submission · read as late 2026

  • “IND-enabling work for IM-1340 is ongoing and we expect to submit an IND for this program to the FDA in mid-2026.”

    matched to IM-1340 · regulatory submission · read as mid-2026

  • ““For varegacestat, the presentation of detailed Phase 3 RINGSIDE data at ASCO and subsequent FDA acceptance of our NDA with a PDUFA target action date of April 28, 2027 represent important steps toward a potential approval and launch.”

    matched to Varegacestat · regulatory decision · read as April 28, 2027

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (17)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Nov 4, 2026ReleaseImmunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026via aggregator→ BD updateIM-1021 delivers a 53% ORR (64% in DLBCL) across all dose levels in heavily pretreated B-NHL patients — the first human proof that the HC74 TOP1i payload engine works, the exact catalyst I said could convert optionality into an asset.
• Nov 2, 2026ReleaseImmunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conferencevia aggregator
• Oct 30, 2026ReleaseImmunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumorsvia aggregatorThe EMA has validated Immunome's Marketing Authorization Application for varegacestat — the EU dossier is now formally under centralized review, checking off the "EU MAA by end of 2026" catalyst I flagged, and bringing the European orphan-designation question I warned about into live play.BD extracted 1 program update from this document → IMNM pipeline
• Oct 26, 2026ReleaseImmunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026BD extracted 1 program update from this document → IMNM pipeline
• Oct 5, 20268-KCurrent report: material agreement, unregistered sale of equity→ BD updateImmunome quietly bought out the entire BMS royalty and milestone burden on varegacestat — paying $20M cash + ~4.4M shares — and now owns the patents outright, transforming the drug's commercial economics ahead of the April 2027 PDUFA date.
• Sep 30, 2026ReleaseImmunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumorsvia aggregator
• Sep 2, 2026ReleaseImmunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
• Aug 11, 2026ReleaseImmunome Reports Second Quarter 2026 Financial Results and Provides Business UpdateBD extracted 1 program update from this document → IMNM pipeline
• Aug 11, 20268-KCurrent report: results of operations · EX-99.1
• Aug 11, 202610-QQuarterly report
• Jun 12, 20268-KCurrent report: shareholder vote
• May 12, 20268-KCurrent report: results of operations · EX-99.1
• May 12, 202610-QQuarterly report
• Apr 24, 2026DEFA14AProxy soliciting material
• Apr 24, 2026DEF 14AProxy statement
• Mar 3, 20268-KCurrent report: results of operations · EX-99.1
• Mar 3, 202610-KAnnual report